Huang Shenghui, Jiang Junshi, Xu Zhiming, Lu Cuncun, Cao Fang, Sang Wengxia, Gong Ting, Li Yanyi
Department of Neurology, Affiliated Hospital of Gansu University of Chinese Medicine.
College of Integrated Traditional Chinese and Western Medicine, Guansu University of Chinese Medicine.
Medicine (Baltimore). 2018 Dec;97(52):e13762. doi: 10.1097/MD.0000000000013762.
Cerebral infarction is a commonly dangerous disease also with high morbidity and mortality. Thrombolytic agent is an effective method to treat it, but their relative efficacy and safety are unclear. A network meta-analysis (NMA) will be conducted to resolve this urgent problem.
The PubMed, Embase, and Cochrane library will be systematically search from their inception to November 2018. All randomized controlled trials (RCTs) will be included this NMA and their risk of bias will be assessed using Cochrane handbook tool. The outcomes of efficacy and safety including: Modified Rankin Scale scores, reperfusion rate, incidence of symptomatic intracerebral hemorrhage and all-cause mortality. A network meta-analysis will be performed using R x64 3.5.1 software and pairwise meta-analysis will be conducted using Stata 12.0 software (Stata Corp., College Station, Texas). Grading of Recommendations Assessment, Development and Evaluation (GRADE) will be used to assess quality of outcomes.
The results of NMA will be published in a peer-reviewed journal.
The NMA will provide a comprehensive evidence summary on thrombolytic agents for patients with cerebral infarction.
脑梗死是一种常见的危险疾病，发病率和死亡率都很高。溶栓剂是治疗该病的有效方法，但其相对疗效和安全性尚不清楚。将进行一项网状Meta分析（NMA）以解决这一紧迫问题。
将对PubMed、Embase和Cochrane图书馆从建库至2018年11月进行系统检索。所有随机对照试验（RCT）都将纳入本NMA，并使用Cochrane手册工具评估其偏倚风险。疗效和安全性结局包括：改良Rankin量表评分、再灌注率、症状性脑出血发生率和全因死亡率。将使用R x64 3.5.1软件进行网状Meta分析，并使用Stata 12.0软件（Stata公司，德克萨斯州大学城）进行成对Meta分析。将采用推荐分级的评估、制定与评价（GRADE）来评估结局质量。
NMA的结果将发表在同行评审期刊上。
NMA将为脑梗死患者的溶栓剂提供全面的证据总结。
